Biogen offered a window into what’s holding up Aduhelm. Investors didn’t like what they saw.

At Morgan Stanley’s healthcare conference, executives detailed how the launch of their Alzheimer’s drug has been slower than expected, due in large part to lingering questions about clinical trial data and insurance coverage.